Medexus Pharmaceuticals Inc.
TSX:MDP.TO · Toronto Stock Exchange
+$0.05 today
Vol 0.02M · Avg 0.05M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
4.3%
avg -56.6%
ROIC
7.4%
avg -25.6%
ROA
1.3%
avg -14.2%
Analysis
ROIC is currently the strongest return metric at 7.4% versus its period average of -25.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kenneth d'Entremont | Chief Executive Officer & Director | $1.56M | — | — | — | — |
Richard Labelle | Chief Operating Officer | $747,427.00 | — | — | — | — |
Bill Poncy | Senior Vice President of Commercial Operations - United States | $615,275.00 | — | — | — | — |
Ian C. Wildgoose Brown | General Counsel & Corporate Secretary | $605,105.00 | — | — | — | — |
Brendon Buschman | Chief Financial Officer | $566,646.00 | — | — | — | — |
Brian Peters | Vice President of Sales & Marketing - United States | $396,695.00 | — | — | — | — |
Tina Byers | Executive of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +32.0% (14yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Forward estimates point to Revenue at +32.0% (14yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Cardiol Therapeutics Inc.
TSX:CRDL.TO
$171.76M
iAnthus Capital Holdings, Inc.
IAN.CN
$69.73M
Decibel Cannabis Company Inc.
DB.V
$69.23M
Vext Science, Inc.
VEXT.CN
$61.92M
Planet 13 Holdings Inc.
PLTH.CN
$60.79M
BioNxt Solutions Inc.
BNXT.CN
$48.08M
C21 Investments Inc.
CXXI.CN
$43.91M
MariMed Inc.
MRMD.CN
$37.93M
The Cannabist Company Holdings Inc.
CBST.NE
$17.47M
InnoCan Pharma Corporation
INNO.CN
$14.17M
Who manages MDP.TO?
Medexus Pharmaceuticals Inc. (MDP.TO) lists 7 active executives. The top listed executive is Bill Poncy, Senior Vice President of Commercial Operations - United States.
Explore More
Continue the stock analysis
Jump to another research area for this company.